About Capricor Therapeutics, Inc. - Common Stock (CAPR)
Capricor Therapeutics is a clinical-stage biotechnology company focused on developing innovative cellular therapeutics to treat rare and chronic diseases. The company primarily works on harnessing the potential of stem cell-derived therapies, with a particular emphasis on cardiac and musculoskeletal conditions. Capricor aims to advance its proprietary technologies through rigorous research and development, striving to bring transformative treatment options to patients with unmet medical needs. By leveraging its expertise and pioneering spirit, Capricor seeks to make significant contributions to the field of regenerative medicine. Read More
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK - September 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK - September 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK - September 3, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
NEW YORK - September 2, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Capricor To Contact Him Directly To Discuss Their Options
NEW YORK - August 28, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK - August 27, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
NEW YORK - August 26, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
